CORRIGENDUM

Decitabine reverses TGF- β 1-induced epithelial–mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis [Corrigendum]

Zhang N, Liu Y, Wang Y, Zhao M, Tu L, Luo F. *Drug Des Devel Ther.* 2017;11:969–983.

as ‘tumor growth factor-beta 1’. The correct definition for TGF- β 1 is ‘transforming growth factor-beta 1’.

Throughout the paper, including Figures, an abbreviation has been defined incorrectly. TGF- β 1 was incorrectly defined

Drug Design, Development and Therapy downloaded from <https://www.dovepress.com/> on 27-Apr-2023
For personal use only.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>